SFV based systems are increasingly the virus vector systems of choice for production of recombinant proteins for research, therapy and diagnosis. They have also been used as the basis for vaccines for a number of pathogens and recent studies indicate that they could be important systems for gene therapy and cancer therapy. For each of these uses the current system has limitations, which could be modified by engineering the viral replicas gene and by targeting to specific cell types. Work on SFV systems has been an exclusively European effort and this project will combine the expertise of the principal EU laboratories. The aim is to research, design, engineer, and test and delivers a new generation of SFV systems for research, biotechnology, vaccination, gene therapy and cancer therapy. These systems will have many important uses in biology, medicine and veterinary medicine and make an important contribution to the quality of life in Europe and worldwide.
Funding SchemeCSC - Cost-sharing contracts
171 77 Stockholm